Business Context and Reporting Period
This Form 8-K Current Report was filed by Envue Medical, Inc. (trading symbol: NAOV) on December 17, 2025. The filing discloses significant changes in executive leadership and employment agreements effective December 17 and December 18, 2025.
Key Financial Metrics and Compensation
The filing does not provide consolidated revenue, profit, cash flow, or liquidity metrics. It details specific compensation arrangements for executive officers:
- CEO Compensation (Doron Besser, M.D.): Annual base salary of $360,000; eligible for an annual bonus up to $180,000 based on performance.
- CEO Equity: Grant of 180,000 restricted stock units (RSUs) representing 9% of fully diluted common stock, with annual adjustments to maintain this percentage.
- CEO Severance: In the event of termination without Cause or resignation for Good Reason (including within 90 days of a Change in Control), the CEO is entitled to a one-time payment equal to 12 months' base salary plus 8 1/3% of base salary in severance.
- Interim CFO Compensation (Nicole Fernandez-McGovern): Annual salary of $300,000 plus expense reimbursement.
Material Changes
The filing reports the following material changes in corporate governance and personnel:
- CEO Employment Agreement: An amended and restated employment agreement was executed with CEO Doron Besser, M.D., superseding the agreement dated February 12, 2025. The new agreement includes significant equity grants and defined severance protections.
- CFO Departure: Stephen Brown ceased to serve as Chief Financial Officer effective December 18, 2025.
- Interim CFO Appointment: Nicole Fernandez-McGovern was appointed Interim Chief Financial Officer via a consulting agreement with RCM Financial Consulting, Inc., effective December 18, 2025.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, revenue outlook, or discussion of market risks. The primary focus is on the terms of the new executive contracts. Key contractual provisions include:
- Termination Terms: Both the CEO and Interim CFO agreements are at-will, terminable with six months' and 60 days' written notice, respectively.
- Change in Control: Specific severance triggers are defined for the CEO in the event of a Change in Control.
- Confidentiality and Covenants: Standard non-solicitation, non-competition, and confidentiality covenants apply to the CEO.
Investor Verification Checklist
- Verify the exact number of outstanding shares to confirm the 9% equity stake granted to the CEO represents the disclosed 180,000 RSUs.
- Review the full text of Exhibit 10.1 (CEO Agreement) and Exhibit 10.2 (CFO Agreement) for omitted confidential terms.
- Assess the impact of the 12-month severance package on the company's cash reserves given the lack of disclosed liquidity data.
- Confirm the transition plan for financial reporting responsibilities following the departure of the previous CFO.